Dovitinib

Generic Name: Dovitinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₁FN_₆O

CAS Number: 405169-16-6

Unique Ingredient Identifier: I35H55G906

Background: Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib.

Indication: Investigated for use/treatment in multiple myeloma and solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: Dovitinib

First Posted Date: 2012-11-22

Last Posted Date: 2022-07-11

Lead Sponsor: Noah Hahn, M.D.

Target Recruit Count: 13

Registration Number: NCT01732107

Locations: 🇺🇸
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Fox Chase Cancer Center Extramural Research Program, Rockledge, Pennsylvania, United States

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Dovitinib

First Posted Date: 2012-11-01

Last Posted Date: 2020-01-07

Lead Sponsor: Asan Medical Center

Target Recruit Count: 19

Registration Number: NCT01719549

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer

Phase 1

Completed

Conditions: Metastatic Clear Cell Renal Cancer

Interventions: Drug: Dovitinib
Drug: Everolimus

First Posted Date: 2012-10-26

Last Posted Date: 2013-11-13

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 17

Registration Number: NCT01714765

Locations: 🇬🇧
Barts Health NHS Trust, London, United Kingdom

Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Phase 1

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Dovitinib
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2012-09-07

Last Posted Date: 2013-02-20

Lead Sponsor: University of Florida

Registration Number: NCT01680796

A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands

Phase 2

Completed

Conditions: Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Salivary Gland Cancers
ACC

Interventions: Drug: Dovitinib

First Posted Date: 2012-09-03

Last Posted Date: 2015-09-17

Lead Sponsor: Ontario Clinical Oncology Group (OCOG)

Target Recruit Count: 21

Registration Number: NCT01678105

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Ontario, Canada
🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada

and more 1 locations

Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: Dovitinib

First Posted Date: 2012-08-31

Last Posted Date: 2018-01-10

Lead Sponsor: University of California, Davis

Target Recruit Count: 10

Registration Number: NCT01676714

Locations: 🇺🇸
University of California Comprehensive Cancer Center, Sacramento, California, United States

Dovitinib in Neuroendocrine Tumors

Phase 2

Completed

Conditions: Advanced Metastatic Paraganglioma
Advanced Metastatic Pheochromocytoma
Recurrent Paraganglioma
Recurrent Pheochromocytoma
Unresectable Paraganglioma
Unresectable Pheochromocytoma

Interventions: Drug: Dovitinib

First Posted Date: 2012-07-10

Last Posted Date: 2020-04-14

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 8

Registration Number: NCT01635907

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: Dovitinib + Paclitaxel
Drug: Dovitinib

First Posted Date: 2012-03-08

Last Posted Date: 2020-04-17

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 13

Registration Number: NCT01548924

Locations: 🇪🇸
Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
🇪🇸
MD Anderson Cancer Centre, Madrid, Spain

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Dovitinib
Drug: Dovitinib Placebo
Drug: Fulvestrant

First Posted Date: 2012-02-08

Last Posted Date: 2016-07-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 97

Registration Number: NCT01528345

Locations: 🇺🇸
City of Hope National Medical Center COH 3, Duarte, California, United States
🇺🇸
University of California San Diego - Moores Cancer Center Moores UCSD Cancer Ctr. SC-1, La Jolla, California, United States
🇺🇸
ProHealth Care, Lake Success, New York, United States

and more 16 locations

Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Phase 2

Completed

Conditions: Adrenocortical Carcinoma

Interventions: Drug: Dovitinib

First Posted Date: 2012-01-23

Last Posted Date: 2017-04-25

Lead Sponsor: Spanish Oncology Genito-Urinary Group

Target Recruit Count: 17

Registration Number: NCT01514526

Locations: 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Spain
🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital Universitario Fundación de Alcorcón, Alcorcón, Madrid, Spain

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy